BACKGROUND: Heart failure (HF) is common among elderly adults. Although multiple studies demonstrate age-related declines in the utilization of evidence-based therapies for coronary artery disease, there are few analyses of HF patients to distinguish possible age-related management differences. METHODS: We analyzed 57,937 HF admissions from January 2005 through April 2007 in 257 hospitals participating in the American Heart Association's Get With The Guidelines-Heart Failure program. Patient characteristics and management were stratified by age groups < or = 65, 66-75, 76-85, and >85 years. Multivariable regression analyses were used to assess the influence of age on use of therapies and inhospital mortality. RESULTS: The mean patient age was 73 +/- 14 years; 18.7% were >85 years of age. Prescriptions of most HF therapies were relatively reduced with age but still remained high overall. Although 88.6% of patients < or = 65 years of age with left ventricular systolic dysfunction were prescribed angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 90.9% were prescribed beta-blockers, among those >85 years of age with left ventricular systolic dysfunction, 79% were prescribed angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 82.7% were prescribed beta-blockers. Regression analysis that accounted for typical confounders demonstrated that older age was associated with diminished utilization of most evidence-based treatment measures as well as increased mortality. CONCLUSIONS: Get With The Guidelines-Heart Failure data demonstrate that guidelines recommended therapies are frequently utilized for older patients with HF, including patients >85 years old. Nonetheless, age-related differences in therapy persist, suggesting that opportunities to improve care still remain.
BACKGROUND:Heart failure (HF) is common among elderly adults. Although multiple studies demonstrate age-related declines in the utilization of evidence-based therapies for coronary artery disease, there are few analyses of HF patients to distinguish possible age-related management differences. METHODS: We analyzed 57,937 HF admissions from January 2005 through April 2007 in 257 hospitals participating in the American Heart Association's Get With The Guidelines-Heart Failure program. Patient characteristics and management were stratified by age groups < or = 65, 66-75, 76-85, and >85 years. Multivariable regression analyses were used to assess the influence of age on use of therapies and inhospital mortality. RESULTS: The mean patient age was 73 +/- 14 years; 18.7% were >85 years of age. Prescriptions of most HF therapies were relatively reduced with age but still remained high overall. Although 88.6% of patients < or = 65 years of age with left ventricular systolic dysfunction were prescribed angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 90.9% were prescribed beta-blockers, among those >85 years of age with left ventricular systolic dysfunction, 79% were prescribed angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and 82.7% were prescribed beta-blockers. Regression analysis that accounted for typical confounders demonstrated that older age was associated with diminished utilization of most evidence-based treatment measures as well as increased mortality. CONCLUSIONS: Get With The Guidelines-Heart Failure data demonstrate that guidelines recommended therapies are frequently utilized for older patients with HF, including patients >85 years old. Nonetheless, age-related differences in therapy persist, suggesting that opportunities to improve care still remain.
Authors: Lindsey R Sangaralingham; Nilay D Shah; Xiaoxi Yao; Véronique L Roger; Shannon M Dunlay Journal: Circ Cardiovasc Qual Outcomes Date: 2016-05-10
Authors: Paul L Hess; Maria V Grau-Sepulveda; Adrian F Hernandez; Eric D Peterson; Deepak L Bhatt; Lee H Schwamm; Clyde W Yancy; Gregg C Fonarow; Sana M Al-Khatib Journal: J Cardiovasc Electrophysiol Date: 2013-02-25
Authors: Michael A Steinman; John B Harlow; Barry M Massie; Peter J Kaboli; Kathy Z Fung; Paul A Heidenreich Journal: J Gen Intern Med Date: 2011-05-21 Impact factor: 5.128
Authors: Alanna C Morrison; Janine F Felix; L Adrienne Cupples; Nicole L Glazer; Laura R Loehr; Abbas Dehghan; Serkalem Demissie; Joshua C Bis; Wayne D Rosamond; Yurii S Aulchenko; Ying A Wang; Talin Haritunians; Aaron R Folsom; Fernando Rivadeneira; Emelia J Benjamin; Thomas Lumley; David Couper; Bruno H Stricker; Christopher J O'Donnell; Kenneth M Rice; Patricia P Chang; Albert Hofman; Daniel Levy; Jerome I Rotter; Ervin R Fox; Andre G Uitterlinden; Thomas J Wang; Bruce M Psaty; James T Willerson; Cornelia M van Duijn; Eric Boerwinkle; Jacqueline C M Witteman; Ramachandran S Vasan; Nicholas L Smith Journal: Circ Cardiovasc Genet Date: 2010-04-17
Authors: Ken Lee Chin; Marina Skiba; Andrew Tonkin; Christopher M Reid; Danny Liew; Henry Krum; Ingrid Hopper Journal: Heart Fail Rev Date: 2016-11 Impact factor: 4.214